Skip Navigation
Search Menu
Find an Expert

 


Allen Dale Everett, M.D.

Photo of Dr. Allen Dale Everett, M.D.

Director of the Pediatric Proteome Center

Professor of Pediatrics

Male

Expertise: Cardiology, Pediatric Cardiology, Pediatric Congenital Heart Disease

Research Interests: Biomarkers of pulmonary hypertension and brain injury; Cardiac Catheterization Outcomes and Quality; Bioinformatics; Vascular injury; Proteomics ...read more

Request an Appointment

I live in Maryland

410-955-6666
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital
Appointment Phone: 410-955-6666

600 N. Wolfe Street
Ross Research Building 1114A
Baltimore, MD 21287 map
Phone: 410-955-5987
Fax: 410-955-0897

Background

Dr. Allen Everett is a professor of pediatrics at the Johns Hopkins University School of Medicine. His areas of clinical expertise include vascular injury, proteomics, biomarker discovery of vascular disease, and cardiac catheterization outcomes and quality measures. Dr. Everett also serves as the director of the Pediatric Proteome Center.

Dr. Everett earned his M.D. from East Tennessee State University. He completed his residency in pediatrics at University of Virginia Health System and performed a fellowship in pediatric cardiology at University of Virginia. Dr. Everett joined the Johns Hopkins faculty in 2003.

He has become the program leader at Johns Hopkins in pediatric biomarker discovery, initially in sickle cell disease and subsequently in other pediatric clinical conditions (birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension). He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies and two proteomic-focused contracts for the NICHD National Children’s Study.

Dr. Everett is an author of 99 peer review papers, two book chapters, editor/author of two books and associate editor for two journals, Cardiology in the Young and PROTEOMICS Clinical Applications. He is a co-developer of PedCathTM cardiac catheterization software with Scientific Software Solutions which has been translated into five languages, has five US biomarker patents filed and brain injury biomarkers licensed to ImmunArray, Ltd., for which he is a consultant.

...read more

Titles

  • Director of the Pediatric Proteome Center
  • Professor of Pediatrics

Departments / Divisions

Education

Degrees

  • MD, East Tennessee State University (1984)

Residencies

  • University of Virginia Health System / Pediatrics (1987)

Fellowships

  • University of Virginia Health System / Pediatric Cardiology (1991)

Board Certifications

  • American Board of Pediatrics / Pediatric Cardiology (1991)

Research & Publications

Research Summary

Dr. Everett has become the program leader at Johns Hopkins in pediatric biomarker discovery, initially in sickle cell disease and subsequently in other pediatric clinical conditions (birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension).

He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies.  Active studies as PI include: NICHD R01 HD086058, "Adult Biomarkers in Neonatal Brain Injury and Development" and NHLBI 1R01HL135114, "Clinical and mechanistic role of HDGF in pulmonary hypertension".

Technology Expertise Keywords

Proteomics; biomarkers; assay development

Selected Publications

View all on Pubmed

Yang J, Nies MK, Fu Z, Damico R, Korley FK, Hassoun PM, Ivy DD, Austin ED, Everett AD. Hepatoma Derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Artery Hypertension, Am J Respir Crit Care Med. 2016 Jun 2. [Epub ahead of print]

Brown JR, Hisey WM, Marshall EJ, Likosky DS, Nichols EL, Everett AD, Pasquali SK, Jacobs ML, Jacobs JP, Parikh CR. Acute Kidney Injury Severity and Long-Term Readmission and Mortality After Cardiac Surgery. Ann Thorac Surg. 2016 Jun 17. pii: S0003-4975(16)30346-0. doi: 10.1016/j.athoracsur.2016.04.020. [Epub ahead of print]

Magruder JT, Hibino N, Collica S, Huaitao Z, Harness HL, Heitmiller ES, Jacobs ML, Cameron DE, Vricella LA, Everett AD. Association of Nadir Oxygen Delivery on Cardiopulmonary Bypass With Serum Glial Fibrillary Acidic Protein Levels in Pediatric Heart Surgery Patients. Interact Cardiovasc Thorac Surg. 2016 Jun 16. pii: ivw194. [Epub ahead of print]

Korley FK, Diaz-Arrastia R., Wu AHB, Yue JK, Manley GT, Sair HI, Van Eyk J, Everett AD and the TRACK-TBI Investigators. Circulating Brain Derived Neurotrophic Factor (BDNF) Has Diagnostic and Prognostic Value in Traumatic Brain Injury. J. Neurotrauma, 2016 Jan 15;33(2):215-225.

Rappold T, Laflam A, Hori D, Brown C, Brandt J, Mintz CD, Sieber F, Gottschalk A, Yenokyan G, Everett A, Hogue CW. Evidence of an association between brain cellular injury and cognitive decline after non-cardiac surgery. Br J Anaesth. 2016 Jan;116(1):83-9.

Patents

A Multi-protein Biomarker Assay for Brain Injury Detection and Outcome
Patent # WO2015009907 A1 | 01/22/2015

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

Biosensor Systems and Related Methods for Detecting Analytes in Aqueous and Biological Environments
Patent # US20140349005 A1 | 11/27/2014

Disclosed herein are biosensor systems and related methods for detecting analytes in aqueous and biologic environments. A biosensor system for detecting binding of an analyte of interest may include a detector configured to detect a change in an electrical property on a surface thereof. The detector may be a FET. The system also may include a passive layer disposed on a top surface of the detector. Further, the system may include a hydrophobic layer disposed on the passive layer. The system also may include a receptor-attachment material configured for binding to an analyte. A receptor may bind to the analyte, and the receptor may be attached to the receptor-attachment material. The binding of the analyte to the receptor can cause the change of the electrical property at the surface. In response to the change for example, a current may change for indicating the binding of the analyte to the receptor.

Assay Reagents for a Neurogranin Diagnostic Kit
Patent # US20140141458 A1 | 05/22/2014

The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

Assay Reagents for a Neurogranin Diagnostic Kit
Patent # EP2707389 A2 | 03/19/2014

The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

Biomarkers of Pulmonary Hypertension
Patent # WO2013090811 A1 | 06/20/2013

Methods are disclosed for predicting or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers.

Activities & Honors

Professional Activities

  • Senior Associate editor, Cardiology in the Young
  • Associate editor, PROTEOMICS Clinical Applications
  • Co-developer, PedCathTM cardiac catheterization software, Scientific Software Solutions
Is this you? Edit Profile